How Investors May Respond To Bio-Rad Laboratories (BIO) Launching StarBright Dyes for Flow Cytometry

• Bio-Rad Laboratories recently announced the launch of its new StarBright Dyes range, beginning with StarBright UltraViolet700, to enhance spectral flow cytometry applications in immunology research.
• This product expansion increases the flexibility and compatibility of Bio-Rad’s offerings, potentially strengthening its position within the growing flow cytometry market segment.
• We'll explore how the addition of StarBright Dyes could enhance Bio-Rad's consumables-driven business and influence its investment outlook.

Find companies with promising cash flow potential yet trading below their fair value.

Bio-Rad Laboratories Investment Narrative Recap

To be a Bio-Rad Laboratories shareholder, you’d need to have conviction in the company’s ability to benefit from consistent demand for consumables and growth in advanced research tools despite persistent pressure on instrument sales and revenue headwinds in key end markets. The StarBright Dyes launch expands the consumables portfolio but does not materially address the biggest short-term risk: continued softness in global instrument demand and related margin pressure.

The recent introduction of the QX Continuum and QX700 Series Droplet Digital PCR platforms aligns with Bio-Rad’s focus on innovation in life science tools, supporting growth in recurring consumables revenue. While these advancements echo the push behind StarBright Dyes, the fundamental challenge remains restoring demand for higher-margin instruments to stabilize earnings.

In stark contrast, investors should also consider the risks of ongoing reimbursement changes and reduced funding in critical diagnostic and academic markets…

Read the full narrative on Bio-Rad Laboratories (it's free!)

Bio-Rad Laboratories is projected to achieve $2.7 billion in revenue and $232.0 million in earnings by 2028. This forecast assumes annual revenue growth of 2.3%, but also a decrease in earnings of $87.2 million from the current level of $319.2 million.

Uncover how Bio-Rad Laboratories' forecasts yield a $326.50 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have set fair values for Bio-Rad Laboratories between US$326.50 and US$903.13, reflecting highly varied outlooks from two private investors. Against this backdrop, persistent reliance on academic and government research funding could have a significant impact on future performance; explore a range of perspectives before making your own assessment.

Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth over 3x more than the current price!

Build Your Own Bio-Rad Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com